---
title: "Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293216572.md"
description: "The ongoing study of 200 patients has shown a low early termination rate of 4.5%, indicating that both the Halneuron® treatment and the placebo have been well tolerated by participants."
datetime: "2026-07-20T12:32:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293216572.md)
  - [en](https://longbridge.com/en/news/293216572.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293216572.md)
generator: "portal-rs"
---

# Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026

The ongoing study of 200 patients has shown a low early termination rate of 4.5%, indicating that both the Halneuron® treatment and the placebo have been well tolerated by participants.

### Related Stocks

- [DWTX.US](https://longbridge.com/en/quote/DWTX.US.md)

## Related News & Research

- [IDEAYA targets year-end 2026 start for Phase 3 IDE849 trial in extensive-stage small cell lung cancer](https://longbridge.com/en/news/297497016.md)
- [Jazz secures FDA approval for Ziihera in advanced HER2+ GEA](https://longbridge.com/en/news/297028123.md)
- [BeOne says FDA approves Tevimbra-based first-line regimen for HER2+ gastroesophageal cancer](https://longbridge.com/en/news/296930925.md)
- [Spyre Therapeutics reports Phase 2 SKYWAY RA data for SPY072 shows statistically significant benefit vs placebo](https://longbridge.com/en/news/297018031.md)
- [Akeso says Phase III ivonescimab-chemo trial in biliary tract cancer meets overall survival endpoint](https://longbridge.com/en/news/297257007.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**